Icotinib versus chemotherapy as adjuvant treatment for stage II–IIIA EGFR-mutant non-small-cell lung cancer (EVIDENCE): a randomised, open-label, phase 3 trial
Jianxing He(First Affiliated Hospital of Guangzhou Medical University), Caicun Zhou(Tongji University), Chunxia Su(Tongji University), Wenhua Liang(First Affiliated Hospital of Guangzhou Medical University), Taiqian Gong(Chinese PLA General Hospital), Wen Lin(Shantou University), Shidong Xu(Harbin Medical University), Jianying Zhou(First Affiliated Hospital Zhejiang University), Yunchao Huang(Zhejiang Chinese Medical University), Jian Zhao(ShanghaiTech University), Xiangning Fu(Tongji University), Lin Wu(Materials Systems (United States)), Xiaoqing Liu(Jiangsu Province Hospital), Qun Chen(Unknown), Yang Liu(Tsinghua University), Chun Chen(Sun Yat-sen University), Zhong Lin Wang(Beijing Institute of Nanoenergy and Nanosystems), Feng Ye(Shanghai Sunshine Rehabilitation Center), Zheng Wang(Shanghai Jiao Tong University), Haitao Ma(Soochow University), Lin Xu(Guangdong Pharmaceutical University), Li Mao(Washington State University), Junke Fu(First Affiliated Hospital of Xi'an Jiaotong University), Zhidong Liu(Capital Medical University), Lieming Ding(Betta Pharmaceuticals (China)), Xingya Li(Zhengzhou University), Guoguang Shao(Jilin University), Weimin Mao(Zhejiang Cancer Hospital), Di Ge(Fudan University), Jian Hu(National Medical Products Administration), Zemin Xiao(The First People's Hospital of Changde), Bing Hu(University of Waterloo)
Cited by 183
Related Papers
Shape-Controlled Synthesis of Colloidal Platinum Nanoparticles
|Science|1996|2.4k
The 2020 report of The Lancet Countdown on health and climate change: responding to converging crises
|The Lancet|2020|1.9k
The 2022 report of the Lancet Countdown on health and climate change: health at the mercy of fossil fuels
|The Lancet|2022|1.6k